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and study eyes was similar. Baseline visual acuity of the study 
eye and that of the fellow eye  were not correlated. Most fel-
low eyes had signs of early AMD, with 34.6% (n = 843) of fel-
low eyes having evidence of scarring.  Conclusions: In pa-
tients in the VIEW studies, most fellow eyes had evidence of 
AMD, highlighting the importance of examining both eyes, 
with close follow-up thereafter, in order to detect and treat 
CNV earlier as needed.  © 2016 S. Karger AG, Basel 
 Introduction 
 Neovascular age-related macular degeneration 
(nAMD) is a leading cause of vision loss and blindness 
among individuals aged >65 years in industrialized coun-
tries  [1, 2] . Early therapies did not produce significant 
improvements in visual acuity (VA)  [2] . The success of 
the first injectable anti-vascular endothelial growth factor 
(VEGF) agent, pegaptanib sodium, suggested that VEGF 
was driving the choroidal neovascularization (CNV) as-
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 Abstract 
 Purpose: The aim was to describe baseline characteristics of 
the fellow eye of patients with neovascular age-related mac-
ular degeneration (nAMD).  Methods: A pooled, post hoc 
analysis of patients with nAMD enrolled in the VIEW studies 
was carried out. The VIEW studies compared intravitreal 
aflibercept (monthly or every 2 months after 3 monthly in-
jections) with monthly ranibizumab. Baseline choroidal neo-
vascularization (CNV) status of fellow eyes and baseline best-
corrected visual acuity (BCVA) and lens status of all eyes were 
evaluated. Additional analyses evaluated the presence of 
drusen and pigment in fellow eyes.  Results: When compar-
ing both eyes, baseline BCVA was worse in 23.8% of fellow 
eyes and in 75.2% of study eyes. Lens status of fellow eyes 
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sociated with nAMD. Later, treatment with monthly ra-
nibizumab was shown to prevent vision loss in most pa-
tients, and to meaningfully improve VA in about one 
third of patients  [3, 4] ; however, the potential risk of side 
effects plus the burden of monthly visits led to efforts to 
decrease injection and monitoring frequency  [2] . 
 Aflibercept, a recombinant fusion protein comprising 
key VEGF-binding domains of human VEGF receptors 1 
and 2 fused to the Fc domain of human immunoglobulin 
G1, binds VEGF and placental growth factor, and dem-
onstrated a higher binding affinity than ranibizumab or 
bevacizumab  [5, 6] in preclinical studies, which could ac-
count for less frequent dosing. The VIEW studies com-
pared intravitreal aflibercept injection, monthly or every 
2 months after 3 initial monthly injections, with monthly 
ranibizumab. At week 52, all groups had similar visual, 
morphologic, and safety outcomes  [2] . 
 Previous reports have described the incidence of new 
CNV in the fellow eye during therapy. CNV in one eye of 
a patient with AMD is a strong risk factor for the develop-
ment of CNV in the fellow eye (annual incidence: 4–19%) 
 [7–9] . Although nAMD trials have reported increased 
rates of CNV development in fellow eyes during therapy, 
perhaps due to more careful monitoring during clinical 
studies  [10, 11] , information on baseline incidence of 
CNV in fellow eyes was not reported. Since early detec-
tion of CNV in the fellow eye may lead to better long-term 
visual outcomes, it may be important to characterize fel-
low eyes at baseline. The aim of this study was, therefore, 
to evaluate the baseline status of fellow eyes and to test the 
hypothesis that patients with worse VA in the fellow eye 
might present earlier, and with better VA in the study eye. 
 Methods 
 A pooled, post hoc analysis of patients enrolled in the VIEW 
studies was carried out in order to characterize the baseline status 
of fellow eyes, with a focus on baseline VA, lens status, and AMD-
associated findings. 
 The VIEW studies (NCT00509795; NCT00637377) were ran-
domized, double-masked, multicenter, parallel-group, active-con-
trolled phase 3 trials that recruited >2,400 patients with treatment-
naïve nAMD from >360 centers worldwide. The trials compared 
standard of care (monthly ranibizumab) with 3 dosing regimens 
(0.5 mg monthly, 2 mg monthly, 2 mg every other month follow-
ing 3 initial monthly injections) of intravitreal aflibercept injection 
 [2] . The VIEW study protocols were approved by the institutional 
review boards or ethics committees for each clinical site and all 
participants provided written informed consent.
 In the original VIEW studies, for patients who met eligibility 
criteria in both eyes, the eye with the worse VA was selected as the 
study eye. In this post hoc analysis, 3 different sources within the 
VIEW database were compared. The Past Medical History and Ad-
verse Event (PMH) data were used to search for previous diagnoses 
of CNV before baseline. The Prior and Concomitant medications 
data (CONMED) used CONMED codes for ‘first use of ranibizum-
ab (Lucentis ® )/bevacizumab (Avastin ® )/pegaptanib (Macugen ® ) 
in fellow eye before baseline’ to search for first use of CNV medica-
tion. The Digital Angiography Reading Center (DARC) database 
 Fig. 1. Distribution of baseline BCVA for 
fellow eye (upper panel) and study eye 
(lower panel). ETDRS = Early Treatment 
Diabetic Retinopathy Study. 
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used ‘Choroidal Neovascularization; Fellow Eye’ to search for ana-
tomic evidence of fellow eye CNV at baseline. Inclusion required the 
identification in  ≥ 1 database. Baseline best-corrected VA (BCVA) 
and lens status were assessed for all eyes. Baseline evidence of cur-
rent/prior CNV, presence of hard/soft drusen, presence of interme-
diate/large drusen, and presence/location of pigment were assessed 
for fellow eyes only. Geographic atrophy could not be evaluated.
 Results 
 Patients 
 Baseline characteristics of fellow eyes versus study eyes 
were described for 2,412 patients from the VIEW studies.
 Baseline BCVA: Study Eye versus Fellow Eye 
 The mean (standard deviation) BCVA was 65.2 (25.8) 
letters ( ∼ 20/50) in fellow eyes versus 53.8 (13.6) letters 
( ∼ 20/80) in study eyes. Severe visual impairment [ ≤ 36 
letters ( ∼ 20/200)] was seen in 16.9% of fellow eyes versus 
12.4% of study eyes. Note that in the VIEW studies, only 
eyes with a letter score of 25–75 letters could be selected 
as study eyes. BCVA >80 letters ( ∼ 20/25) was seen in 
33.2% of fellow eyes versus 0.2% of study eyes. Baseline 
BCVA was worse in fellow eyes in 23.8% of patients and 
in study eyes in 75.2% of patients (0.3% missing; 0.6% 
baseline VA equal in both eyes). Distribution of baseline 
BCVA is shown in  figure 1 .
 Baseline Characteristics: Fellow Eye 
 Overall, 2.5% of fellow eyes had anti-VEGF use prior 
to the first study day. Most fellow eyes had signs of AMD 
at baseline. Baseline drusen and pigment characteristics 
were assessed; only 10.0% (n = 226) of fellow eyes did not 
have drusen and only 11.8% (n = 132/1,120; pigment in-
formation only available for VIEW 1) did not have pig-
ment at baseline ( table 1 ). Breakdown of VA in fellow eyes 
with/without CNV is shown in  figure 2 . At baseline, 
843/2,412 patients (34.6%) presented with scarring (pres-
ence of fibrosis) as a sign of prior CNV. Of these 843, most 
(64.8%; n = 546) were categorized in >1 database as hav-
ing CNV. Some patients were categorized as having CNV 
in only 1 database (16.1%; n = 136 categorized in DARC 
only, 19.0%; n = 161 categorized in PMH only). The lens 
status of fellow eyes was similar to that of study eyes; 
pseudophakia was seen in 34.3% (fellow eyes) and 38.0% 
(study eyes). 
 Baseline Study Eye VA versus Baseline Fellow Eye VA 
 We examined whether patients with worse fellow eye 
VA present earlier and with better VA in the study eye. 
The mean (SD) study eye VA was 53.7 (13.8) when the 
baseline fellow eye VA was  ≥ 50 letters, and 54.0 (12.7) 
when the baseline fellow eye VA was <50 letters, confirm-
ing that our hypothesis was not supported.
 Discussion 
 AMD is a bilateral disease, and risk of neovasculariza-
tion in a fellow eye increases over time after initial diag-
nosis  [12] . Hence, it is important to determine the status 
of both eyes at diagnosis. The current analysis showed 
 Table 1. Baseline drusen and pigment characteristics in fellow eyes
Drusena
Hard 2,011 (88.6)
Soft 1,693 (74.5)
None 226 (10.0)
Number of intermediate/large drusenb (n = 2,256)
Not entered 102 (4.5)
0 – 5 1,124 (49.8)
6 – 10 255 (11.3)
11 – 20 259 (11.5)
>20 522 (23.1)
Pigmentc (n = 1,120)
Extrafoveal 985 (87.9)
Subfoveal 223 (19.9)
None 132 (11.8)
 Figures are numbers with percentages in parentheses. 
Characteristics are not mutually exclusive. a Hard drusen have 
well-defined/distinct borders (usually small/intermediate); soft 
drusen have confluent/indistinct borders (usually intermediate/
large). b Intermediate ≥63 to <125 μm; large ≥125 μm. c Information 
only available for VIEW 1 patients (n = 1,120).
 Fig. 2. Baseline BCVA and CNV in the fellow eye. ETDRS = Early 
Treatment Diabetic Retinopathy Study. 
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that most fellow eyes in the VIEW studies had signs of 
AMD at baseline, confirmed by the presence of drusen 
and pigment. Approximately one third of the fellow eyes 
also had evidence of CNV at baseline. 
 The average baseline condition of fellow eyes at the 
time these trials commenced may have been worse than 
the average baseline condition of fellow eyes today. 
Management of nAMD is constantly evolving with 
availability of new therapies and diagnostic tools, as well 
as ongoing evaluation of optimal dosing regimens. His-
torically, nAMD was treated with laser photocoagula-
tion, which often caused a permanent loss of central vi-
sion. Earlier treatments that followed generally de-
creased severe vision loss with less damage to associated 
choroid and retina  [13] . In the current study,  ∼ 35% of 
patients showed evidence of scarring. It was not until the 
early 2000s that VEGF inhibitors became available as 
treatment options for nAMD that stabilize or signifi-
cantly improve VA. Questions remain about best dosing 
regimens, and efforts to minimize the burden of fre-
quent injections sometimes result in undertreatment. 
As advanced therapies continue to be introduced and 
care of patients with nAMD progresses, it is expected 
that the prognosis for these patients will improve, result-
ing in better outcomes. 
 It can be speculated that if one eye already has suffered 
visual loss due to CNV, the second eye would be followed 
closely and changes would be noticeable early. Early di-
agnosis should lead to presenting vision in the second eye 
being better than that in the initial eye. However, this was 
not supported by the current analysis, which found no 
difference in baseline VA of study eyes as a function of 
baseline VA of fellow eyes. 
 This analysis was potentially limited by the fact that 
specific inclusion and exclusion criteria are imposed on 
patients enrolled in clinical trials, and this may intro-
duce a selection bias. For example, for those patients 
who met eligibility criteria in both eyes, the eye with the 
worse VA was selected as the study eye. However, the 
better-seeing eye was selected as the study eye in 
575/2,412 (23.8%) patients in VIEW 1 and 2; in these 
patients, the baseline BCVA score in the fellow eye was 
<25 letters in 294/575 (51.1%) patients; in the remaining 
281/575 (48.9%) patients, other reasons were present 
not to select the worse eye as the study eye. Nevertheless, 
these patient populations may not truly reflect those 
seen in real-world clinical practice; this, and the resul-
tant characterization of the patients in this analysis, 
should be taken into consideration when interpreting 
these results. 
 Conclusions 
 The risk of development of CNV in untreated eyes af-
ter diagnosis of the initial eyes has been well described; 
however, information on the prevalence of CNV in the 
second eye at the time of the initial diagnosis is scarce. In 
this first report describing baseline characteristics of fel-
low eyes using data from the VIEW study, most patients 
had evidence of AMD characteristics in fellow eyes at 
baseline, with one third presenting with signs of CNV. As 
AMD is a bilateral disease, it is important to evaluate the 
status of both eyes during clinical examination even if 
only 1 eye presents with CNV in order to be able to detect 
and treat early for optimal outcomes. Close follow-up is 
needed, as fellow eyes are at high risk of developing CNV 
in the near future.
 Acknowledgements 
 The authors take full responsibility for the scope, direction, and 
content of the manuscript; all authors have read and approved the 
final submitted manuscript. Additional contributions to the man-
uscript were made by Richard Morton, MSc. Medical writing sup-
port was provided by Michelle Olsher, PhD, and Leigh Prevost, 
BSc Pharm Hons, of PAREXEL, which was funded by Bayer Phar-
maceuticals.
 Disclosure Statement 
 Sebastian Wolf: consultant to and/or advisory board member 
for Alcon, Allergan, Bayer Pharmaceuticals, Heidelberg Engi-
neering, Novartis, Roche, Zeiss;  Francesco Bandello: advisory 
board member for Allergan, Novartis, Théa, Bayer-Schering, Pfiz-
er, Alcon, Bausch and Lomb, Genentech, Alimera Sciences, Sano-
fi-Aventis, Thrombogenics, and Hoffmann-La Roche, and data 
safety monitoring board member for Novagali Pharma;  Anat 
Loewenstein: consultant to Allergan, Alimera, Bayer Pharmaceu-
ticals, LaRoche, Novartis, Notal Vision, and Teva, advisory board 
member for Novartis;  Jason Slakter: grant research support for 
Digital Angiography Reading Center, Bayer Pharmaceuticals, Ge-
nentech, Genzyme, GSK, Lpath, Ohr, Oraya, Regeneron, Sanofi-
Aventis, Santen, Thrombogenics, and Tyrogenex, consultant to 
Genentech, Ohr, Oraya, and Regeneron, stock ownership: SKS 
Ocular and Ohr Pharmaceutical;  Todd Katz: employee of  Bayer 
Pharmaceuticals;  Olaf Sowade: employee of Bayer Pharmaceuti-
cals;  Jean-Francois Korobelnik: consultant for Alcon, Alimera, Al-
lergan, Bayer Pharmaceuticals, Horus, Novartis, Roche, Thea, and 
Zeiss.
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.9
.5
6 
- 8
/2
9/
20
16
 1
0:
46
:1
9 
AM
 Characteristics of Fellow Eye in nAMD Ophthalmologica
DOI: 10.1159/000447725
5
 References 
 1 Congdon NG, Friedman DS, Lietman T: Im-
portant causes of visual impairment in the 
world today. JAMA 2003; 290: 2057–2060. 
 2 Heier JS, Brown DM, Chong V, Korobelnik 
JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, 
Ogura Y, Yancopoulos GD, Stahl N, Vitti R, 
Berliner AJ, Soo Y, Anderesi M, Groetzbach 
G, Sommerauer B, Sandbrink R, Simader C, 
Schmidt-Erfurth U: Intravitreal aflibercept 
(VEGF trap-eye) in wet age-related macular 
degeneration. Ophthalmology 2012;  119: 
 2537–2548. 
 3 Brown DM, Kaiser PK, Michels M, Soubrane 
G, Heier JS, Kim RY, Sy JP, Schneider S: Ra-
nibizumab versus verteporfin for neovascular 
age-related macular degeneration. N Engl J 
Med 2006; 355: 1432–1444. 
 4 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, 
Kaiser PK, Chung CY, Kim RY: Ranibizumab 
for neovascular age-related macular degen-
eration. N Engl J Med 2006; 355: 1419–1431. 
 5 Holash J, Davis S, Papadopoulos N, Croll SD, 
Ho L, Russell M, Boland P, Leidich R, Hylton 
D, Burova E, Ioffe E, Huang T, Radziejewski C, 
Bailey K, Fandl JP, Daly T, Wiegand SJ, Yanco-
poulos GD, Rudge JS: VEGF-Trap: a VEGF 
blocker with potent antitumor effects. Proc 
Natl Acad Sci USA 2002; 99: 11393–11398. 
 6 Papadopoulos N, Martin J, Ruan Q, Rafique 
A, Rosconi MP, Shi E, Pyles EA, Yancopoulos 
GD, Stahl N, Wiegand SJ: Binding and neu-
tralization of vascular endothelial growth fac-
tor (VEGF) and related ligands by VEGF 
Trap, ranibizumab and bevacizumab. Angio-
genesis 2012; 15: 171–185. 
 7 Macular Photocoagulation Study Group: Risk 
factors for choroidal neovascularization in 
the second eye of patients with juxtafoveal or 
subfoveal choroidal neovascularization sec-
ondary to age-related macular degeneration. 
Arch Ophthalmol 1997; 115: 741–747. 
 8 Solomon SD, Jefferys JL, Hawkins BS, Bressler 
NM: Incident choroidal neovascularization in 
fellow eyes of patients with unilateral subfo-
veal choroidal neovascularization secondary 
to age-related macular degeneration: SST re-
port No 20 from the Submacular Surgery Tri-
als Research Group. Arch Ophthalmol 2007; 
 125: 1323–1330. 
 9 Wang JJ, Rochtchina E, Lee AJ, Chia EM, 
Smith W, Cumming RG, Mitchell P: Ten-year 
incidence and progression of age-related 
maculopathy: the blue Mountains Eye Study. 
Ophthalmology 2007; 114: 92–98. 
 10 Barbazetto IA, Saroj N, Shapiro H, Wong P, 
Ho AC, Freund KB: Incidence of new choroi-
dal neovascularization in fellow eyes of pa-
tients treated in the MARINA and ANCHOR 
trials. Am J Ophthalmol 2010; 149: 939–946. 
 11 Maguire MG, Daniel E, Shah AR, Grunwald 
JE, Hagstrom SA, Avery RL, Huang J, Martin 
RW, Roth DB, Castellarin AA, Bakri SJ, Fine 
SL, Martin DF: Incidence of choroidal neo-
vascularization in the fellow eye in the com-
parison of age-related macular degeneration 
treatments trials. Ophthalmology 2013; 120: 
 2035–2041. 
 12 Amissah-Arthur KN, Panneerselvam S, Nar-
endran N, Yang YC: Optical coherence to-
mography changes before the development of 
choroidal neovascularization in second eyes 
of patients with bilateral wet macular degen-
eration. Eye (Lond) 2012; 26: 394–399. 
 13 Brown DM, Regillo CD: Anti-VEGF agents in 
the treatment of neovascular age-related mac-
ular degeneration: applying clinical trial re-
sults to the treatment of everyday patients. 
Am J Ophthalmol 2007; 144: 627–637. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.9
.5
6 
- 8
/2
9/
20
16
 1
0:
46
:1
9 
AM
